Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
Chronic kidney disease
Dotinurad
Hyperuricemia
Kidney dysfunction
Uric acid
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
28
04
2023
accepted:
05
03
2024
medline:
18
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
epublish
Résumé
In this study, we aimed to clarify the beneficial effects of urate-lowering treatment with the novel agent dotinurad on renal function in patients with chronic kidney disease (CKD) and hyperuricemia (HUA). Thirty-five patients with CKD (mean age 65.4 ± 14.8 years, 23 men) diagnosed with HUA were recruited. Changes in eGFR before and after dotinurad administration were assessed. Patients first underwent a 3-month observation period and then 3 months treatment with dotinurad. During the observation period, mean eGFR (mL/min/1.73 m Dotinurad administration to patients with CKD and HUA appears to be beneficial in restoring kidney function. Dotinurad may represent a potential medication for the prevention of kidney function decline caused by HUA.
Sections du résumé
BACKGROUND
BACKGROUND
In this study, we aimed to clarify the beneficial effects of urate-lowering treatment with the novel agent dotinurad on renal function in patients with chronic kidney disease (CKD) and hyperuricemia (HUA).
METHODS
METHODS
Thirty-five patients with CKD (mean age 65.4 ± 14.8 years, 23 men) diagnosed with HUA were recruited. Changes in eGFR before and after dotinurad administration were assessed. Patients first underwent a 3-month observation period and then 3 months treatment with dotinurad.
RESULTS
RESULTS
During the observation period, mean eGFR (mL/min/1.73 m
CONCLUSION
CONCLUSIONS
Dotinurad administration to patients with CKD and HUA appears to be beneficial in restoring kidney function. Dotinurad may represent a potential medication for the prevention of kidney function decline caused by HUA.
Identifiants
pubmed: 38491453
doi: 10.1186/s12882-024-03535-9
pii: 10.1186/s12882-024-03535-9
doi:
Substances chimiques
Uric Acid
268B43MJ25
dotinurad
305EB53128
Uricosuric Agents
0
Benzothiazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Informations de copyright
© 2024. The Author(s).
Références
Hakoda M, Kasagi F. Future trends for the number of gout patients in Japan. Gout Uric Nucleic Acids. 2020;44:33–9. https://doi.org/10.14867/gnamtsunyo.44.1_33 . (in Japanese).
doi: 10.14867/gnamtsunyo.44.1_33
Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–50. https://doi.org/10.1053/j.ajkd.2004.06.006 .
doi: 10.1053/j.ajkd.2004.06.006
pubmed: 15384015
Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407–13. https://doi.org/10.1681/ASN.2008010080 .
doi: 10.1681/ASN.2008010080
pubmed: 18799720
pmcid: 2588108
Kawashima M, Wada K, Ohta H, et al. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol. 2011;12:31. https://doi.org/10.1186/1471-2369-12-31 .
doi: 10.1186/1471-2369-12-31
pubmed: 21722384
pmcid: 3146922
Japanese Society of Nephrology. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin Exp Nephrol. 2019;23:1–15. https://doi.org/10.1007/s10157-018-1648-1 .
doi: 10.1007/s10157-018-1648-1
Hisatome I, Ichida K, Mineo I, et al. Japanese Society of Gout and Uric & Nucleic Acids 2019 guidelines for management of hyperuricemia and gout 3rd edition. Gout Uric Nucleic Acids. 2020;44(suppl):S1–40. https://doi.org/10.14867/gnamtsunyo.44.Supplement_sp-1 .
doi: 10.14867/gnamtsunyo.44.Supplement_sp-1
Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92. https://doi.org/10.1053/j.ajkd.2008.12.034 .
doi: 10.1053/j.ajkd.2008.12.034
pubmed: 19339088
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Perico N, Remuzzi G. Chronic kidney disease: a research and public health priority. Nephrol Dial Transplant. 2012;27(suppl 3):iii19–26. https://doi.org/10.1093/ndt/gfs284 .
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. https://doi.org/10.1056/NEJMoa041031 .
doi: 10.1056/NEJMoa041031
pubmed: 15385656
Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population: the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5. https://doi.org/10.1093/ndt/gfm051 .
doi: 10.1093/ndt/gfm051
pubmed: 17395659
Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82. https://doi.org/10.1016/S0140-6736(14)61601-9 .
doi: 10.1016/S0140-6736(14)61601-9
pubmed: 25777665
Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382:2504–13. https://doi.org/10.1056/NEJMoa1915833 .
doi: 10.1056/NEJMoa1915833
pubmed: 32579811
Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with Stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72:798–810. https://doi.org/10.1053/j.ajkd.2018.06.028 .
doi: 10.1053/j.ajkd.2018.06.028
pubmed: 30177485
Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in Type 1 diabetes. N Engl J Med. 2020;382:2493–503. https://doi.org/10.1056/NEJMoa1916624 .
doi: 10.1056/NEJMoa1916624
pubmed: 32579810
pmcid: 7375708
Seegmiller JE, Erazier PD. Biochemical considerations of the renal damage of gout. Ann Rheum Dis. 1966;25(6 Suppl):668–72. https://doi.org/10.1136/ard.25.Suppl_6.668 .
doi: 10.1136/ard.25.Suppl_6.668
pubmed: 5226513
pmcid: 2453423
Sellmayr M, Petzsche MRH, Ma Q, et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol. 2020;31:2773–92. https://doi.org/10.1681/ASN.2020040523 .
doi: 10.1681/ASN.2020040523
pubmed: 32938648
pmcid: 7790211
Bardin T, Nguyen QD, Tran KM, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99:218–26. https://doi.org/10.1016/j.kint.2020.08.024 .
doi: 10.1016/j.kint.2020.08.024
pubmed: 32898570